Synbiotic
PreclinicalSmall molecule
Synbiotic is one of 52 small molecule programs targeting Crohn's Disease. It is currently in Preclinical.
1
Indications
3
Total Trials
0
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
74 competitors in Crohn's Disease
#DrugCompanyPhaseTrials
1Stelara
Johnson & JohnsonApproved
Trexall
Jazz PharmaceuticalsApproved
Lamprene
NovartisApproved
Rocaltrol
Jazz PharmaceuticalsApproved
Medrol
PfizerApproved
Calciferol
Jazz PharmaceuticalsApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Levulan
Sun Pharmaceutical Industries, Inc.Approved
Rayos
RRoxane Laboratories
Approved
Tremfya
Johnson & JohnsonPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Insulin resistance2 trials
Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT02127125·69 enrolled
Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim 1)
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT02124759·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Synbiotic. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details